Brain structural connectivity atrophy in Alzheimer's disease by Amoroso, Nicola et al.
ar
X
iv
:1
70
9.
02
36
9v
2 
 [p
hy
sic
s.m
ed
-p
h]
  9
 Se
p 2
01
7
Brain structural connectivity atrophy in Alzheimer’s
disease
Nicola Amoroso1,2, Marianna La Rocca1,2,*, Stefania Bruno3, Tommaso Maggipinto1,2,
Alfonso Monaco2, Roberto Bellotti**1,2, Sabina Tangaro**2, and for the Alzheimer’s
Disease Neuroimaging Initiative§
1Universita` degli studi di Bari, Dipartimento Interateneo di Fisica, Italy.
2Istituto Nazionale di Fisica Nucleare, sez. di Bari, Italy.
3Blackheath Brain Injury Rehabilitation Centre, London, UK.
*email to: marianna.larocca@ba.infn.it
**RB and ST: equal last-author contribution
ABSTRACT
Analysis and quantification of brain structural changes, using Magnetic resonance imaging (MRI), are increas-
ingly used to define novel biomarkers of brain pathologies, such as Alzheimer’s disease (AD). Network-based
models of the brain have shown that both local and global topological properties can reveal patterns of disease
propagation. On the other hand, intra-subject descriptions cannot exploit the whole information context, acces-
sible through inter-subject comparisons. To address this, we developed a novel approach, which models brain
structural connectivity atrophy with a multiplex network and summarizes it within a classification score. On an
independent dataset multiplex networks were able to correctly segregate, from normal controls (NC), AD patients
and subjects with mild cognitive impairment that will convert to AD (cMCI) with an accuracy of, respectively,
0.86± 0.01 and 0.84± 0.01. The model also shows that illness effects are maximally detected by parceling the
brain in equal volumes of 3000 mm3 (”patches”), without any a priori segmentation based on anatomical fea-
tures. A direct comparison to standard voxel-based morphometry on the same dataset showed that the multiplex
network approach had higher sensitivity. This method is general and can have twofold potential applications:
providing a reliable tool for clinical trials and a disease signature of neurodegenerative pathologies.
Introduction
Alzheimer’s disease (AD) is a progressive, neurodegenerative disease accounting for most cases of dementia after
the age of 65. It is expected that over 115 million people will develop AD by 20501. Illness related brain changes
can be detected in vivo with magnetic resonance imaging (MRI) and neuroimaging has been playing an increasingly
important role for the diagnosis of neurodegenerative disorders2, 3 to the extent that it has been incorporated in the
diagnostic criteria for AD4. It is now accepted that the neurodegenerative cascade in AD begins in the brain years,
decades even, before the clinical and radiological manifestations of the illness. The dementia is preceded by a
prodromal phase of mild cognitive impairment5, and this, in turn, by a pre-clinical phase6 of variable duration.
Understanding the biological changes, occurring in these early phases, is of paramount importance, as it would
open a window of opportunity for future disease-modifying treatments. While it is clear that neurodegeneration
in AD occurs in a rather stereotyped fashion in the majority of cases7, 8, it is not known exactly what drives the
propagation of the disease within an individual, and what is behind the variations in the patterns of atrophy between
individuals. To which extent neurodegeneration propagates through anatomical contiguity, or through preferential
pathways of structural or functional connectivity is yet to be clarified, but network-based approaches can yield a
better understanding of these phenomena.
§Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database
(adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or pro-
vided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at:
http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.
MRI can provide significant information on large-scale topological organization of the brain9–11 and graph
theory has been widely used to study both functional and structural connectivity11–14 for AD and, more in general,
for neurodegenerative disease characterization15 . These studies reported altered local and global graph properties
in AD, supporting the clinical relevance of brain networks, especially within group-wise association studies16, 17.
Up to now the different graph theory strategies used to model and describe the brain11–13, 18–21 have been based on
two distinct approaches22 : (i) voxel-wise and (ii) region of interest analyses. We propose here a novel approach
combining the interpretability of a voxel-wise description, without its intrinsic computational burden and noise
sensitivity23 , and the robustness of region of interest methods, avoiding a priori assumptions in terms of disease
effects or segmentation accuracy24. In addition, as brain disease has often a diffuse effect, affecting multiple voxels,
but not necessarily corresponding to entire anatomical structures, the proposed approach has the potential to better
suit the description of pathological changes in the brain, reflecting biological variability.
Specifically for network science, recent studies have investigated the limitations of traditional approaches to
describe real systems25–27 and have pointed out that context information plays a fundamental role. Here we intro-
duce an approach that segments the whole brain in rectangular boxes, from now onward referred to as “patches”,
representing the nodes of a network modeling each subject. The network connections are pairwise Pearson’s cor-
relations between the nodes. This is aimed at investigating graph-based properties from the different perspective
of multiplex networks (from now onward also multiplexes) and introducing a novel concept, namely structural
connectivity atrophy. Multiplexes are multi-layer systems with a fixed number of nodes that can be linked in differ-
ent interacting layers, to investigate inter-subject characterization, rather than group-wise differences. In this study
multiplex-based features are exploited to efficiently model AD-related atrophy patterns; these faetures are then used
within a random forest classifier to correctly segregate normal controls (NC) from AD patients and subjects with
mild cognitive impairment that will convert to AD (cMCI). We demonstrate how a structural connectivity atrophy
can be used to describe inter-subject variability relating it to the emergence of statistically significant AD patterns
altering the topological organization of the brain.
Results
Scale selection and informative content
Graph theory provides tools to concisely quantify the properties of complex networks that describe interrelation-
ships (represented by edges) between the objects of interest (represented by nodes). In this work, for each subject,
and thus for each MRI brain scan, we built a weighted undirected network whose N nodes were rectangular brain
patches and whose connections were defined by measuring their pairwise Pearson’s correlation, see Figure 1 for a
pictorial representation.
In order to detect structural local changes of the brain, we considered the strength s of each patch, measuring
the intensity of its connections. Strength does not take into account if the number of connections is preserved, thus
we included in our representation the nodal degree k which is the number of existing connections and the inverse
participation ratio Y evaluating how unevenly the weights of the links of the node are distributed28 . To capture inter-
subject variations, we introduced the conditional values of strength s(k) and inverse participation Y (k). Finally, to
capture intra-subjects changes, we considered the distribution degrees k′ of the whole cohort and analogously
defined the quantities s(k′) and Y (k′). In conclusion we obtained a 8-dimensional feature representation for each
node.
There is no a priori knowledge determining the dimension of patches and, therefore, the number of nodes
N that should be used to model a brain with a network. Thus, we firstly investigated if a privileged dimension
existed in order to maximize classification accuracy to distinguish controls and patients. To this aim, we used a
first random forest classifier for feature selection and a second random forest to summarize network measures in
a unique network atrophy score, within a 5-fold cross-validation framework. This score allowed subjects’ classi-
fication. Experimental results on a mixed cohort of 38 AD and 29 NC, namely Dtrain, showed an accurate and
stable classification performance within the [2250,3200] voxel (mm3) range, corresponding approximately to 500
patches, with variations lower than 5%. This range established the optimal patch dimension for the NC-AD clas-
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Figure 1. At the top: the multiplex network with M layers, representing a study subject, and N nodes,
representing brain patches. At the bottom: the representation of multi-links for the different pairs of network
nodes. Within each layer different nodes can be connected with a link and a specific weight. This context
information is then used to detect different patterns.
sification, best results were obtained with N = 549 patches. In addition, we performed a second classification test
using structural morphological features obtained by FreeSurfer29, instead of multiplex features. The accuracy of
the proposed methodology was on average 0.88 with a 0.01 standard error (sensitivity and a specificity respectively
0.90± 0.01 and 0.88± 0.02) while with FreeSurfer features we obtained 0.83± 0.01 (sensitvity 0.86± 0.01 and
specificity 0.79±0.01). This result confirms the effectiveness of the multiplex characterization and the possibility
to use our framework to discriminate controls from patients using only MRI data.
Anatomical characterization
Once the optimal dimension of multiplex network had been fixed we investigated on Dtrain the most significant
features according to their classification importance and consequently the related anatomical districts. The reason
was twofold: reduce the data dimensionality and gain clinical insight.
Starting from the initial network of 549 nodes, for each subject we determined which regions were able to effec-
tively distinguish controls from patients, thus outlining 32 significant patches, 18 (∼ 56%) in the left hemisphere
and 14 in the right; these regions included 27 different cortical and sub-cortical regions listed in Figure 2 in order
of significance. Further details about significance measures for both features and anatomical districts are provided
in Methods section. As a region can be included in different patches (provided at least one of its voxels belongs to
the considered patch), only most significant p-value entries are reported.
In Figure 3 some representative brain axial planes are shown, as well as the Harvard-Oxford atlas30 we used
for this assessment.
In the left hemisphere, patches corresponding to amygdala, hippocampus, para-hippocampal gyrus, pallidum and
putamen showed the strongest association to AD (p = 0.0001). For cingulate and para-cingulate giri, pre-cuneus,
cuneus, and occipital cortex p = 0.001. Other significant patches (p = 0.002) were located in middle frontal gyrus
and pre-frontal gyrus, nucleus accumbens, brain stem and thalamus.
On the right, p = 0.0001 for orbito-frontal cortex, insular cortex, prarahippocampal gyrus, planum polare and
planum temporale; p = 0.001 for the parahippocampal-amygdalar complex, occipital pole, pre- and post-central
gyri, supramarginal gyrus, middle and superior temporal gyri; p = 0.002 for inferior, middle and superior frontal
gyri, frontal pole, and paracingulate gyrus. Interestingly, the right frontal lobe involvement was more evident.
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Figure 2. Regions related to AD in order of significance. Accumbens (Ac), Amygdala (A), Brain-Stem (BS), Caudate (Ca), Cingulate Gyrus (cG) anterior
division (ad), Cuneal Cortex (cC), Frontal Operculum and Orbital Cortex (fopC) and (foC), Frontal Pole (fP), Hippocampus (H), Inferior Frontal Gyrus (ifG) pars opercularis and pars triangularis (po) and (pt),
Inferior Temporal Gyrus (itG) anterior division and temporoccipital part (tp), Insular Cortex (iC), Intracalcarine Cortex (icC), Lateral Occipital Cortex (loC) superior division (sd), Lateral Ventrical (lV),
Lingual Gyrus (lG), Middle Frontal and Temporal Gyrus (mfG) and (mtG), Occipital Pole (oP), Pallidum (Pa), Paracingulate and Parahippocampal Gyrus (paG) and (phG), Planum Polare and Temporale (PP)
and (PT). Postcentral and Precentral Gyrus (poG) and (prG), Precuneous Coretx (pC), Putamen (Pu), Subcallosal Cortex (sC), Superior Frontal Gyrus (sfG), Superior Parietal Lobule (spL), Superior Temporal
Gyrus (stG), Supracalcarine Cortex (scC), Supramarginal Gyrus (sG), Temporal Fusiform and Temporal Occipital Fusiform Cortex (tfC) and (tofC), Temporal Pole (tP), Thalamus (Th). In parentheses:
anterior, posterior and superior division (ad,pd,sd) and temporooccipital part (tp).
Figure 3. This figure shows six axial planes (left panel) with the significant patches outlined in green (p-value
< 0.01), and on the right, the Harvard-Oxford Atlas used for the patch anatomical localization.
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Multiplex Networks vs Voxel Based Morphometry
In order to establish if this new approach may offer any advantages over existing widely used methods, we analyzed
the same data set with Voxel Based Morphometry (VBM)31.
We followed the standard prescription for VBM with the publicly available SPM 12 suite1. Firstly, a segmen-
tation of brain tissues was performed, followed by non-linear normalization with the SPM tool DARTEL to create
a study specific template. Secondly, we performed a smoothing with an isotropic Gaussian filter with a full width
at half maximum of 8 mm. Lastly, a two-sample analysis was performed with a t statistics to investigate signif-
icant group-wise differences in atrophy between NC and AD on training subjects. Significant voxels, with 5%
family-wise correction, are represented in Figure 4.
Figure 4. A voxel based morphometry analysis shows bilateral areas of significantly reduced grey matter density
in patients with AD, in medial temporal lobe structures, such as hippocampus and amygdala, more prominent on
the left as expected.
The VBM analysis showed significant reduction in grey matter density only in bilateral peri-hippocampal re-
gions, more prominent of the left. Compared to the proposed methodology, able to detect 32 significant regions,
VBM showed a largely decreased sensitivity. Since the VBM analysis confirmed that left-sided changes were more
prominent, two dedicated tests were carried out to further explore the lateralization. Firstly, we used only multiplex
features inherent to the left (right) hemisphere and trained the classification models. We found that left patches
were able to discriminate NC from AD patients with an accuracy of 0.87± 0.01 while right hemisphere features
were able to reach the accuracy value 0.85± 0.01. Left hemisphere remained responsible for a greater part of the
overall information of the multiplex framework, which was 0.88±0.01.
However, each patch summarizes a network of interrelationships with other patches independently from its
spatial collocation. As an example, the strength of a node denotes the sum of its connections, the fact that a node
of the left hemisphere is significantly related to AD does not prevent its strength to be the result of its correlation
with the right hemisphere. As a consequence, a second test was performed. We built the multiplexes of left and
right hemispheres separately, thus disregarding one hemisphere. Classification accuracy for NC-AD when using
left (right) multiplex was 0.83± 0.01 (0.81± 0.01), thus confirming a greater involvement of the left hemisphere
but also signaling a definite deterioration of the information content if compared with the whole brain multiplex.
Robustness and generalization
To investigate if classification performance based on netowrk atrophy was related to the random permutation of
voxels inside a patch, we firstly shuffled a varying number of voxel within each patch, while keeping the patch
decomposition stable, thus affecting the Pearson’s correlation pairwise measurement. Then we measured the clas-
sification accuracy. The training results are presented in Figure 5.
The test was repeated 100 times increasing the size of the shuffle by 500 voxels at the time. It could be noticed
that for small variations, under 1000 voxels, performance did not suffer a significant deterioration; but with 2500
voxel permutation a drastic drop of the performance was observed, a value comparable with the dimensional scale
determined in section .
1http://www.fil.ion.ucl.ac.uk/spm/software/spm12/
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Figure 5. Accuracy varying with the number of permuted voxel within a patch. Classification performance
decreased as the number of shuffled voxels was increased. Noticeably, a drastic drop was observed when the
shuffle reached values of about 2500 ∼ 3000 voxels.
To further assess the method robustness we also performed a classical non-parametric statistical permutation
test. This consisted in the permutation of the clinical labels of each subject belonging to Dtrain. We performed 1000
random permutation and observed that the classification accuracy was 0.50±0.05.
Training set randomization effectively established that the multiplex framework was able to model a significant
structure in the Dtrain data between the multiplex features and the clinical label. Moreover, given the normality of
the performance distribution obtained by permuting the labels, it was possible to assign a p-value to the performance
obtained without permutations. The result showed that the multiplex model was able to identify a significant
(p < .001) class structure within the Dtrain data. Otherwise, it would not have been possible to reject the null
hypothesis underlying this test, i. e. that labels and features were independent, so that in fact no difference really
existed between the classes.
As a further assessment, we performed a binary classification on an independent test set Dtest , incuding 48
AD, 52 NC and 48 cMCI, for the NC-AD and NC-cMCI cases. The analysis was repeated using 100 bootstrapped
Dtest sets to provide a measurement of the performance uncertainty. We found in terms of accuracy respectively
0.86±0.01 and 0.84±0.01. The respective specificity were 0.74±0.01 and 0.72±0.01, while sensitivity reached
higher values for both cases: 0.96± 0.01 and 0.94± 0.01. Remarkably, the NC-cMCI classification performance
compared well with NC-AD classification confirming the method reliability and its informative content.
The small, but significant, performance deterioration (training accuracy was 0.88±0.01, see section ) could be
expected, mainly because even if the test perturbation of the training multiplex was considered small, it should not
be completely neglected. The implementation of larger training sets could in principle mitigate this effect.
Discussion
The proposed approach aims at modeling brain atrophy in AD through inter-subject multiplex networks whose
nodes are represented by brain patches and edges by pairwise Pearson’s correlations. Basing on multiplex features
we introduced a network atrophy score. This score allowed a robust classification performance over a broad range
of Pearson’s correlations and with the use of other similarity metrics (see sections “Threshold Assessment” and
“Similarity Metric Study” of the Supplementary Materials).
An optimal volume size for the detection of AD effects, maximizing the informative content of the multiplex,
was identified as ranging from 2250 to 3200 mm3. it is worthwhile to note that this range was comparable with the
size of several brain structures related to AD, such as the hippocampus, therefore suggesting it as an ideal multiplex
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dimension for AD characterization.
The high sensitivity of the method in the detection of illness related brain changes was demonstrated by the
number of regions, 32, that were identified as significantly associated with AD. The detected regions comprised
hippocampus and para-hippocampal-amygdalar complex, pallidum and putamen, cingulate and paracingulate giri,
pre-cuneus, cuneus, and occipital cortex, middle frontal gyrus, pre-central gyrus, accumbens, sub-callosal cortex
and brain stem.
The cingulate cortex early involvement in AD pathology, has been amply demonstrated by functional and
structural studies32, 33. The same is true for posterior areas, such as cuneus and pre-cuneus, also known to be
affected by the illness in early stages33, 34. As to the involvement of subcortical gray matter in AD, this has also been
recognized, and shown to correlate with cognitive impairment35. Volume loss of the nucleus accumbens was found
to increase the risk of progression from MCI to AD36. The brain stem is a key area in the early pathophysiology
of Parkinson’s disease, another common neurodegenerative disorder, and alterations of the brain stem in AD have
been shown both in vivo37 and post-mortem38.
It was striking how VBM on the same data set was able to detect only atrophy of the perihippocampal regions.
The method here described seems more sensitive than standard VBM39, while studies adopting advanced VBM
methodologies have also shown better results40. The method outlined the involvement of 32 significant brain
regions, but only 22 concerned single-layer measures; thus, the multiplex model thus allowed a consistent increment
(+46%) in sensitivity. The results also confirmed asymmetry in the spatial distribution of significant patches, mostly
located in the left hemisphere, in keeping with several other studies41, 42. This asymmetry has a direct effect on the
informative content (see “Left/Right Characterization” of the Supplementary Materials).
As to the application of this methodology to disease classification studies, we evaluated the method robustness
on an independent setDtest and confirmed its reliability for discriminating both AD patients and cMCI subjects from
controls. Classification performances are accurate, it should be noticed the obtained results are comparable with
recent classification-focused studies3, 43, 44. To provide a diagnosis support system, although results are encouraging
in this sense, was not the end goal of this work; however, the multiplex model is able to efficiently capture diseased
patterns and inter-subject variability thanks to the specific multi-layer features this model can introduces. An even
more refined classification could have been achieved including, as suggested by our previous works, structural
features45 or longitudinal information46 . In addition, the method has great versatility and lends itself to a variety
of purposes, including the identification of “disease signature” for more anatomically heterogeneous forms of
neurodegenerative disorder, such as tauophathies or synucleinopathies, where the model could be enriched with
additional clinical or genetic data.
Conclusion
In this paper we propose a novel approach based on multiplex networks to characterize brain structural variations
related to AD. We investigated the information content provided by multiplex networks and showed that they
produce an accurate modeling of the disease.
We demonstrated how this framework is able to provide a robust method for AD characterization: (i) it shows
the existence of an optimal scale for the description of disease effects of [2250,3200] voxels, which reflects the
size of brain structures relevant in AD, such as the hippocampi. (ii) The method does not require any a priori
human expert segmentation and correctly identifies cerebral region significantly related to AD. It also confirms
that AD pathology is more prominent in the left hemisphere. (iii) Multiplex networks are a robust and effective
method to describe disease patterns. Multiplex-based features allow, on the independent test set Dtest , the accurate
classification of AD patients, with an accuracy of 0.86±0.01, and cMCI subjects, with an accuracy of 0.84±0.01,
from NC subjects.
The information content provided by multiplex characterization was able to efficiently detect disease patterns.
Also, the method is very suitable to application to longitudinal studies, ideally in association with functional imag-
ing, to improve our understanding of the different patterns of neurodegeneration in different diseases. The impact
of variables such as the degree of atrophy, disease duration, site or scanner type could also be investigated in further
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studies.
Methods
Subjects
In this work we used a training a set Dtrain of 67 T1 MRI scans, composed of 29 normal controls (NC) and 38
AD subjects, from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). These subjects belonged to a larger
benchmark dataset selected in order to obtain a compact yet representative sample of ADNI47; the dataset included
also MCI subjects, which were excluded as not relevant to this study. We also employed an independent test set
of 148 subjects Dtest , composed by 52 NC, 48 AD and 48 subjects with mild cognitive impairment converting
to AD (cMCI). Dtest subjects were randomly chosen within the whole ADNI in order to match the demographic
characteristics of training subjects. The training sample (67) and the test sample (148) are of sufficient size for the
construction of robust classification models48, 49. cMCI subjects had converted to AD in a time range of [30,108]
months subsequent to the initial assessment. All 215 participants underwent whole-brain MRI at 34 different sites.
Both 1.5 T and 3.0 T scans were included in Dtrain and Dtest .
ADNI images consisted of MPRAGEMRI brain scans, which were normalized with the MNI152 brain template
of size of 197 × 233 × 189 mm3 and resolution of 1× 1× 1 mm3; as a consequence voxels and mm3 can
be interchangeably used. Clinical and demographic information, including the Mini Mental State Examination
(MMSE) score, age, years of education and sex for the Dtrain and Dtest is detailed in Supplementary Materials .
Multiplex network construction
A standard image processing procedure was carried out with the Oxford FMRIB library FSL50. Firstly, MRI scan
intensity differences were normalized, then intra-cranial regions were extracted with the FSL Brain Extraction
Tool (BET). Secondly, spatial normalization was performed to co-register the different images into the common
coordinate space MNI152; an affine registration, with default configuration, was performed with the FSL Linear
Registration Tool (FLIRT). Linear registration is preferred to a non-linear for the methodology to be robust to subtle
local differences, due for example to subject morphological variability, or small registration failures. Finally, using
the template brain coordinates, we automatically segmented the brain of each subject into the two hemispheres
and, starting from the medial longitudinal fissure plane, uniformly divided each hemisphere in an equal number of
rectangular (l1× l2× l3) patches, covering the whole brain, see Figure 6. Only those patches overlapping with the
template brain for more than 10% were kept.
Figure 6. The figure qualitatively shows how MRI brain scans are segmented in rectangular patches of
dimensions l1× l2× l3. Firstly, the brains normalized to MNI152 template are divided in left and right
hemispheres using the medial longitudinal fissure, then the patch dimensions are set and finally the brain is
segmented. Only patches overlapping the brain for at least the 10% of their content are kept, others are discarded.
Patches were the nodes of a network whose connections represented the grade of similarity between them.
Several similarity metrics were explored (see the “Similarity Metric Study” section in Supplementary Materials)
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and Pearson’s correlation was finally preferred.
For each subject, we built an undirected weighted network with edges defined by pairwise Pearson’s correlation
among patches. Therefore, multiplex network G = {G1,G2, ...,Gα , ...,GM} was, in this case, a collection of single
subject weighted networks Gα = (N,Eα ,Wα) sharing a common number of nodes N, while the set of links Eα and
the inherent weights wi j ∈Wα change depending on the layer α . According to this notation, each network Gα can
also be represented by the corresponding adjacency matrix Aα = a
α
i j.
Pearson’s correlation admits continuous values in the [−1,1] interval. Negative correlations were disregarded.
It is worth noting that negative correlations can be found, for example, between patches in which gray matter and
white matter undergo a left-right inversion. As a result, distinguishing positive and negative correlations would
include in the multiplex model a left-right bias. As asymmetry is a common characteristic of atrophy in AD, it was
decided to consider undirected networks. In addition, we decided to threshold the networks by setting to 0 all con-
nections whose absolute correlation was less than moderate (|r|< .3), in order to exclude noisy interrelationships in
the model, and reducing as much as possible the loss of important links. For higher correlations, weights were kept
in the model, thus resulting in a weighted undirected network representation for each subject. An investigation on
how the threshold affects the multiplex network ability to detect diseased patterns is also reported in the “Threshold
Study” section in Supplementary Materials.
Multiplex features
In a multiplex it is possible to introduce several topological characteristics that are usually adopted to describe
a complex network28. In our approach we employed the following indicators: the strength sαi and the inverse
participation ratio Y αi of a node i in layer α :
sαi =
N
∑
j=1
wαi j (1)
Y αi =
N
∑
j=1
(
wαi j
sαi
)2
(2)
Strength measurements denote which nodes are more relevant within the network describing a single layer (i. e. a
subject) of the multiplex. Inverse participation ratio attains the heterogeneity of the weight distribution within each
layer.
Along with these two measurements we also evaluated the conditional means of strength s(k)α and inverse
participation Y (k)α against the nodes with degree k:
s(k)α =
1
Nk
N
∑
i=1
sαi δ (k
α
i ,k) (3)
Y (k)α =
1
Nk
N
∑
i=1
Y αi δ (k
α
i ,k) (4)
Summation is extended over the Nk nodes having degree k; as summation includes a Kronecker δ function, the
only non-null terms, for both strength and inverse participation, are referred to nodes i of the layer α whose
degree is k. These quantities help to understand how weights are distributed within each layer, thus, for example,
distinguishing whether, on average, the weights of central nodes and less connected nodes are identically distributed
or not. Several studies have already pointed out, especially with group-wise single layer approaches51 , how these
features can describe significant differences among healthy and diseased subjects.
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However, it is reasonable to assume that further evidence of significant differences between subjects, can arise
from the context information provided by the multiplex framework. Accordingly, this information content was
exploited by considering the aggregate adjacency matrix Amulti = amultii j where:
amultii j = {1 i f ∃α |wαi j > 0 ∧ 0 otherwise} (5)
The matrix Amulti naturally allowed us to re-introduce the previous measurements within a global perspective. In
fact, it was possible to compute for each node an aggregated degree and then use it to weight the previously defined
strength and inverse participation. Analogously, we used Amulti to define the aggregate degree for each node and
then re-computing the conditional means. In this way we introduced in the description of each node the information
produced by the whole multiplex.
In conclusion each network was described by 8N features (4N single layer and 4N multiplex features), resulting
in a M× 8N feature representation. It is worthwhile to note that this characterization was independent from the
clinical status of the subjects as the multiplex had been built blindly to diagnosis. This base of knowledge was then
investigated with supervised machine learning models to extract specific disease effect patterns.
Classification and Clinical feature importance
The multiplex characterization of the images yielded a simple matrix representation, which could be used to feed
machine learning models, and unveil discriminating anatomical patterns. The number of features f , involved in this
approach, could easily reach values ranging from∼ 103 to∼ 104 outnumbering the number of the available training
samples. Thus, to prevent over-training issues, arising from the curse of dimensionality and assess the multiplex
framework, a feature selection was necessary. A flowchart of the whole feature selection method is represented in
Figure 7.
Figure 7. A flowchart of the feature selection methodology: the features, stored in a matrix, are used to train a
random forest model, this model provides a feature important estimation; the procedure is cross-validated with a
5-fold for 1000 times, at each round taking into account the selected feature. Finally, a statistical test of hypothesis
establishes which features have been selected a significant number of times.
A 5-fold cross-validation feature importance selection was performed within a wrapper-based strategy. We
randomly divided 1000 times Atrain in a training and a validation test. For each cross-validation round we built
a multiplex model on training subjects, then we computed the related training multiplex features and the overall
matrix Atrain. For test subjects, single layer features were straightforwardly computed. Features accounting the
whole multiplex structure were in turn computed adding the test subject to the training multiplex but keeping fixed
Atrain. The reason for this choice can be justified considering the perturbation induced by the addition of one layer
is small.
For each cross-validation round, we trained a first random forest classifier and selected the most important
features. In particular, we measured the total decrease in node impurities, in terms of Gini index, from splitting
on the variable, averaged over all trees. The selected features were stored for later use and used to train a second
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random forest classifier which was used to predict the diagnosis of the validation subjects. In both cases random
forests were grown with 500 trees, a number large enough for the out-of-bag error to reach the typical training
plateau.
At each split
√
f features were randomly sampled, thus, for each cross-validation round, different features
were selected; to determine the most important features, we measured the overall occurrence rate of each feature,
interpreting it as a success rate. As a consequence, we compared the probability to observe such occurrence with
a binomial distribution and an experimental p-value could be computed to test the randomness hypothesis. To
select a more exiguous number of features a p-value < 0.01 threshold was set, then we established which ones had
shown a significant probability of occurrence. Once the best features had been selected, we used them to train a
new ensemble model on Dtrain and tested it on Dtest to assess the method robustness and evaluate the informative
content carried by multiplex features.
It is worth noting that features like strength and inverse participation have a direct interpretation, being directly
related to a single patch of the brain network whilst conditional means, by definition, are related to several nodes
sharing a common degree k. For classification purposes this is not an issue, being based on computed features; on
the contrary this is relevant in order to provide an anatomical interpretation and a diagnostic value of the features
selected. Again, for each significant feature we determined with the same strategy which anatomical districts had
show a significant association to AD.
Supplementary Material
Demographic Information
Clinical and demographic information, including the Mini Mental State Examination (MMSE) score, age, years of
education and sex for the Dtrain and Dtest is detailed in Table 1. Except for MMSE scores, there were no significant
differences among the three groups according to a Wilcoxon test.
Dtrain Dtest Total
Disease status AD (38) NC (29) AD (48) NC (52) cMCI (48) 215
Female/male 18/20 13/16 22/26 25/27 21/27 99/116
Age (years) 74 ± 8 75 ± 6 78 ± 6 75 ± 6 76 ± 6 76 ± 6
Education (years) 15 ± 3 17 ± 3 15 ± 3 16 ± 3 15 ± 3 16 ± 3
MMSE 23 ± 2 29 ± 1 24 ± 2 29 ± 1 27 ± 2 26 ± 2
n sites 23 19 26 29 18 34
Table 1. Group size and sex information are reported for each class. The table also provides age, years of
education and MMSE (mean and standard deviation). The disease status reported is as assessed at baseline visit.
MMSE score resulted statistically different for all groups with a p-value < 0.01 except between Dtrain and Dtest
normal controls and between Dtrain and Dtest AD patients.
Threshold Study
Since this approach could in principle heavily depend on the threshold value adopted to discard negligible corre-
lations, the threshold values ranging from 0 to 0.8 were explored with a 0.1 step. Then, for each threshold value
a different multiplex was constructed. The patch dimension adopted was 3000 mm3. The training classification
performance was measured in terms of accuracy, see Figure 8
The classification accuracy reached its maximum value with a 0.3 threshold value and it remained stable over
0.85 for a large range of correlations [0.2,0.5]. Outside this range a performance drop was observed. With lower
or higher threshold performances showed a significant decrease, especially above the 0.8 threshold; in which case
more of the 50% of the networks resulted empty. This is because lower threshold values introduced noisy correla-
tions within the model, thus concealing the effective network information, whilst greater threshold values were too
penalizing as informative links were neglected.
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Figure 8. The figure shows the accuracy as a function of the threshold that changes from 0 to 0.8. The best
accuracy is obtained in correspondence of a threshold value of 0.3.
Similarity Metric Study
We investigated different similarity measures52 to define the presence of an edge between two generic patches si
and s j. In addition to the Pearson’s correlation (PC), we studied:
• Mutual Information (MI):
MIi j = H(si)+H(s j)−H(si,s j)
where H(si) and H(s j) are the Shannon entropies related to the patches si, s j and H(si,s j) is their joint
Shannon entropy.
• Mean Square Differences (MSD):
MSDi j =
1
D
D
∑
k=1
(ski − skj)2
with ski , s
k
j being the voxel intensity within a patch and D the total number of voxels.
• Hellinger distance (HD):
HDi j =
1
D
√
D
∑
k=1
(
√
ski −
√
skj)
2
as usual D is the patch size and ski , s
k
j are the voxel intensities.
• Kolmogorov Smirnov non parametric statistic test (KST) quantifying the shape difference between gray level
distributions of the patch pairs.
• Unpaired t statistic test (UtT) evaluating the difference between means of the patch gray level distribution
pairs in terms of standard error.
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For MI the same 0.3 threshold used for Pearson’s Correlation was adopted. For MSD and HD, adjacency matrix
was obtained computing the complementary of the normalized MSD and HD matrix and placing to zero the values
< 0.3. Finally for KS and unpaired t test, adjacency matrix was given by the complementary of the normalized
test statistic matrix, putting to zero the elements rejecting respectively the null hypothesis of patch distribution and
mean equality with a p-value < 0.05. A complete summary of the metric study, including sensitivity and specificity,
is reported in Table 2:
Similarity Metric Accuracy Sensitivity Specificity
Pearson’s Correlation 0.88±0.01 0.90±0.01 0.88±0.02
Mutual Information 0.87±0.01 0.90±0.01 0.87±0.02
Mean Square Differences 0.81±0.01 0.84±0.01 0.80±0.02
Hellinger Distances 0.80±0.01 0.83±0.01 0.77±0.02
Kolmogorov Smirnov test 0.77±0.01 0.82±0.01 0.77±0.02
Unpaired t test 0.75±0.01 0.79±0.01 0.73±0.02
Table 2. For each similarity measurement, accuracy sensitivity and specificity with relative standard errors are
shown. Best performing metrics are indicated in bold.
PC and MI are intrinsically normalized metrics which also exploit the spatial correspondence of voxels within
a patch; they gave best results. MSD and HD, lacking normalization, suffer a significant performance drop. KST
and UtT consider respectively only the shape and the average of the patch gray level distribution gave lower perfor-
mances.
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